The Estrogen Patch Shortage: What Women Should Know

When hormone therapy helps you manage menopause symptoms, an unexpected “out of stock” message can feel unsettling. Finding the right treatment takes time, and wondering whether your next refill will be available adds another concern to an already busy life.

Women across the United States are experiencing difficulty obtaining estradiol patches. Understanding what is happening, and where to go for help, can be helpful.

Why are estrogen patches hard to find?

Estradiol is a form of estrogen used in many menopause treatments. Patches deliver it through the skin, and demand has grown substantially.

The American Society of Health-System Pharmacists lists shortages affecting several manufacturers’ estradiol patches. Its August 12 update describes backorders, intermittent shipments, and allocation, meaning some products are distributed in limited quantities. Availability differs by manufacturer and strength, with some products remaining available.

The FDA acknowledged these access problems on September 3, 2026. It reported that patch supplies had nearly doubled over the previous year, yet patients were still having trouble finding their usual products. Manufacturers are adding shifts, equipment, and production capacity, but patches require specialized manufacturing processes that take time to expand.

The result is a frustrating mismatch: more patches are being produced, but the particular product a woman needs may still be unavailable at her pharmacy.

More women are seeking estrogen treatment

The increase in estrogen use began before the most recent FDA labeling changes.

An April 2026 Truveta analysis found that estrogen-based hormone therapy prescribing more than doubled between January 2018 and February 2026 among women represented in its prescription dataset. In its separate dispensing analysis, patch use more than tripled. Women ages 45–54 experienced particularly strong growth in prescribing. These findings describe the studied populations, rather than every woman in the United States.

Greater public awareness and more open conversations about menopause have helped women recognize symptoms and seek care. The research also reflects a growing interest in treatment options that were once discussed less often.

For appropriately selected patients, that interest is supported by evidence. Hormone therapy is the most effective treatment for hot flashes and night sweats. The Menopause Society states that benefits generally outweigh risks for healthy, symptomatic women younger than 60 and within 10 years of menopause onset, with individualized assessment and follow-up.

How the FDA’s “black box” warning changes fit in

On November 10, 2025, the FDA requested changes to menopause hormone therapy labeling. On February 12, 2026, it announced approval of the first six updated product labels, removing statements about cardiovascular disease, breast cancer, and probable dementia from their boxed warnings—the agency’s most prominent safety warnings.

The changes were intended to better communicate how benefits and risks vary with the patient and treatment. Cardiovascular and breast cancer information remains elsewhere in systemic hormone therapy labeling. The boxed warning about endometrial cancer also remains for systemic estrogen-alone products. Individual medical history still matters.

The warning changes likely contributed to increased demand. The FDA explicitly reports that demand rose following its November 2025 action. However, the available evidence does not establish how much of the shortage resulted from that announcement. Growing treatment use and manufacturing constraints were also part of the picture.

Why pharmacy problems can be complicated

A shortage can create several obstacles at once. A pharmacy may have one patch strength but lack another. A replacement brand may have different application instructions. An insurance plan may cover the unavailable product but charge substantially more for an alternative.

CNN reporting documented patients transferring prescriptions, changing brands, and encountering these coverage problems. Pharmacists and prescribers are spending additional time locating products and arranging suitable alternatives.

If your refill is affected, contact your pharmacist and prescriber before your supply runs out. They can check other products and discuss whether another estrogen formulation is appropriate. Avoid changing your dose or treatment schedule on your own.

A treatment approach that does not depend on patch refills

At Hormone Health and Wellness of Colorado, Dr. Kathy Howe offers bioidentical hormone pellet therapy. Dr. Howe is the practice’s medical director and is board certified physician and peptide therapy certified. Meet Dr. Howe

The practice sources its prescribed pellets from U.S. compounding pharmacies it knows and trusts. Pellets are placed beneath the skin and release hormones over time, so treatment does not require recurring estradiol patch refills. The clinic describes pellet therapy as its primary hormone treatment method.

For patients already receiving estrogen through pellets, a patch backorder does not interrupt the hormone release from pellets already in place. That can remove the worry of searching multiple pharmacies for the next box of patches.

Understanding your options supports better care

“Bioidentical” means a hormone has the same molecular structure as a hormone produced by the body. FDA-approved estradiol patches, gels, and tablets can also be bioidentical.

The American College of Obstetricians and Gynecologists recommends FDA-approved menopausal hormone therapies over compounded preparations when suitable approved options are available. Pellets also require careful discussion because their effects cannot be promptly stopped or adjusted after insertion. Patients should understand the evidence, potential adverse effects, and available alternatives before choosing treatment.

Women who have a uterus generally also need progesterone or another appropriate progestogen with systemic estrogen to protect the uterine lining.

You deserve a clear plan for feeling better

Menopause symptoms deserve attention, and prescription difficulties deserve practical help. A conversation with Dr. Howe can help you explore whether hormone therapy fits your health history, symptoms, and preferences. We want you to understand the benefits and limitations of the clinic’s pellet approach.

For women in Grand Junction and across Western Colorado, Hormone Health and Wellness of Colorado offers a local place to begin that conversation.

If estrogen refill problems have left you feeling uncertain, contact the clinic to schedule a consultation. Bring your current medication list and your questions. Understanding your options is the first step toward a treatment plan you can feel comfortable following.